
Seismic Therapeutic is a biotechnology company revolutionizing immunology drug discovery and development by integrating machine learning with biologics drug discovery elements such as structural biology, protein engineering, and translational immunology. The company operates a proprietary IMPACT platform to create optimized biologic therapies targeting dysregulated adaptive immunity for autoimmune diseases. With a strong leadership team and scientific founders, Seismic has a growing pipeline of best-in-class and first-in-class biologics, including clinical and preclinical candidates. Their approach emphasizes hyper-collaboration, inclusivity, and patient-centric innovation, positioning them as a leader in the immunology therapeutics space with significant traction in clinical trials and a robust investor syndicate.

Seismic Therapeutic is a biotechnology company revolutionizing immunology drug discovery and development by integrating machine learning with biologics drug discovery elements such as structural biology, protein engineering, and translational immunology. The company operates a proprietary IMPACT platform to create optimized biologic therapies targeting dysregulated adaptive immunity for autoimmune diseases. With a strong leadership team and scientific founders, Seismic has a growing pipeline of best-in-class and first-in-class biologics, including clinical and preclinical candidates. Their approach emphasizes hyper-collaboration, inclusivity, and patient-centric innovation, positioning them as a leader in the immunology therapeutics space with significant traction in clinical trials and a robust investor syndicate.
Stage: Clinical-stage immunology biotechnology company
Core technology: IMPACT platform — machine learning + structural biology for biologic design
Lead programs: Includes S-1117 (IgG protease) and S-4321 (PD-1 agonist); programs targeting IgE/allergic diseases
Funding: Raised a $121M Series B (Dec 4, 2023); total reported capital $222M
Founders & backers: Founders include Jo Viney and Alan Crane; investors include Lightspeed, Bessemer, GV, Polaris, Amgen Ventures and others
Autoimmune diseases, inflammatory diseases, allergic diseases
Biotechnology Research
$101,000,000
Launch financing; participants included founding investor Timothy A. Springer, Polaris Partners, GV, Boxer Capital, Samsara BioCapital, management and founders.
$121,000,000
Included new investors (Amgen Ventures, Codon Capital, Alexandria Venture Investments, Gaingels, GC&H) plus existing investors such as Lightspeed, Polaris, GV, Boxer Capital, Samsara BioCapital, and Timothy A. Springer; press release stated total capital raised $222M.
“Backed by a broad life-sciences investor syndicate including venture firms (Lightspeed, Bessemer, GV, Polaris) and strategic investors (Amgen Ventures, Alexandria Venture Investments) and notable individual investors.”
| Company |
|---|